Avidity Biosciences to Participate in Upcoming Investor Conferences
Avidity Biosciences, Inc. (NASDAQ: RNA) has announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Avidity Biosciences, Inc. (NASDAQ: RNA) has announced its participation in two upcoming investor conferences. The Wells Fargo Virtual Healthcare Conference will take place on September 9, 2021, featuring a fireside chat at 11:20am ET. The Chardan Virtual 5th Annual Genetic Medicines Conference is scheduled for October 5, 2021, with a panel discussion at 12noon ET and a fireside chat at 1:30pm ET. Interested parties can access live webcasts and replays on Avidity's website.
Avidity aims to revolutionize RNA therapeutics through its Antibody Oligonucleotide Conjugates (AOCs™), with promising therapies in development for diseases like myotonic dystrophy and Duchenne Muscular Dystrophy.
Details
News Market Reaction – RNA
The recorded move for RNA in the trading session of this news was +9.13%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LA JOLLA, Calif., Aug. 31, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ: RNA) a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Avidity management team will be participating at the following conferences:
2021 Wells Fargo Virtual Healthcare Conference
September 9th, 2021
11:20am ET – Fireside Chat
Chardan Virtual 5th Annual Genetic Medicines Conference
October 5th, 2021
12noon ET – Panel titled "RNA-based Targeted Delivery Approaches"
1:30pm ET – Fireside Chat
Live webcasts of each event, as well as an archived replay of the webcasts following each event, will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCsTM). Avidity's proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1 (DM1). The FDA has cleared Avidity to proceed with the Phase 1/2 MARINATM trial of AOC 1001 in adults with DM1. Its advancing and expanding pipeline also includes programs in facioscapulohumeral muscular dystrophy (FSHD), Duchenne Muscular Dystrophy (DMD), muscle atrophy and Pompe disease. The company is planning for AOC 1044, the lead of three programs for the treatment of DMD, and its AOC FSHD program to enter the clinic in 2022. Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Avidity is headquartered in La Jolla, CA. For more information about our science, pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and Twitter.
Company & Investors Contact:
Kath Gallagher
kath.gallagher@aviditybio.com
(858) 401-7900
Media Contact:
Cherise Adkins
cadkins@spectrumscience.com
(301) 267-4161
View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conferences-301364495.html
SOURCE Avidity Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.